We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICH Updates Safety Guideline With Periodic Benefit-Risk Evaluation Reports
ICH Updates Safety Guideline With Periodic Benefit-Risk Evaluation Reports
April 6, 2012
Drugmakers should provide separate estimates of cumulative and interval patient exposure to marketed drugs and provide justification when an estimate of the number of patients exposed can’t be obtained, according to an International Conference on Harmonisation (ICH) draft guideline on periodic benefit-risk evaluation reports (PBRER).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor